JP2013544078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544078A5 JP2013544078A5 JP2013534142A JP2013534142A JP2013544078A5 JP 2013544078 A5 JP2013544078 A5 JP 2013544078A5 JP 2013534142 A JP2013534142 A JP 2013534142A JP 2013534142 A JP2013534142 A JP 2013534142A JP 2013544078 A5 JP2013544078 A5 JP 2013544078A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- seq
- administration
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- 206010039705 Scleritis Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 201000011588 macular keratitis Diseases 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000057041 human TNF Human genes 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40579810P | 2010-10-22 | 2010-10-22 | |
| US61/405,798 | 2010-10-22 | ||
| US201161484749P | 2011-05-11 | 2011-05-11 | |
| US61/484,749 | 2011-05-11 | ||
| PCT/CH2011/000256 WO2012051734A1 (en) | 2010-10-22 | 2011-10-24 | Stable and soluble antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151924A Division JP2015193664A (ja) | 2010-10-22 | 2015-07-31 | 安定で可溶性の抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544078A JP2013544078A (ja) | 2013-12-12 |
| JP2013544078A5 true JP2013544078A5 (enExample) | 2014-06-05 |
| JP6245985B2 JP6245985B2 (ja) | 2017-12-13 |
Family
ID=44897558
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534142A Active JP6245985B2 (ja) | 2010-10-22 | 2011-10-24 | 安定で可溶性の抗体 |
| JP2015151924A Withdrawn JP2015193664A (ja) | 2010-10-22 | 2015-07-31 | 安定で可溶性の抗体 |
| JP2017142892A Active JP7148228B2 (ja) | 2010-10-22 | 2017-07-24 | 安定で可溶性の抗体 |
| JP2018227992A Pending JP2019054814A (ja) | 2010-10-22 | 2018-12-05 | 安定で可溶性の抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151924A Withdrawn JP2015193664A (ja) | 2010-10-22 | 2015-07-31 | 安定で可溶性の抗体 |
| JP2017142892A Active JP7148228B2 (ja) | 2010-10-22 | 2017-07-24 | 安定で可溶性の抗体 |
| JP2018227992A Pending JP2019054814A (ja) | 2010-10-22 | 2018-12-05 | 安定で可溶性の抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8545849B2 (enExample) |
| EP (2) | EP2630159B1 (enExample) |
| JP (4) | JP6245985B2 (enExample) |
| KR (4) | KR20190016137A (enExample) |
| CN (2) | CN103154033B (enExample) |
| AR (1) | AR083495A1 (enExample) |
| AU (1) | AU2011318179B2 (enExample) |
| BR (1) | BR112013010949B1 (enExample) |
| CA (1) | CA2814766C (enExample) |
| CL (2) | CL2013001089A1 (enExample) |
| CO (1) | CO6741152A2 (enExample) |
| CY (1) | CY1119941T1 (enExample) |
| MX (2) | MX351499B (enExample) |
| PH (1) | PH12013500675B1 (enExample) |
| PL (1) | PL2630159T3 (enExample) |
| RU (2) | RU2558298C2 (enExample) |
| TW (3) | TWI702230B (enExample) |
| UA (1) | UA111340C2 (enExample) |
| UY (1) | UY33679A (enExample) |
| WO (1) | WO2012051734A1 (enExample) |
| ZA (1) | ZA201302537B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038432T2 (hu) * | 2008-06-25 | 2018-10-29 | Esbatech Alcon Biomed Res Unit | Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával |
| UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| AR088403A1 (es) * | 2011-10-20 | 2014-05-28 | Esbatech A Novartis Co Llc | Anticuerpo de union a multiples antigenos estable |
| JP6184982B2 (ja) | 2012-02-02 | 2017-08-23 | エスバテック − ア ノバルティス カンパニー エルエルシー | 点眼用抗体含有徐放性製剤 |
| JP6578206B2 (ja) * | 2012-07-19 | 2019-09-18 | レッドウッド バイオサイエンス， インコーポレイテッド | Ｃｄ２２に特異的な抗体およびその使用方法 |
| CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
| EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
| US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
| IL287947B2 (en) | 2014-10-23 | 2024-08-01 | Amgen Inc | Viscosity reduction of pharmaceutical preparations |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| ES2908470T3 (es) | 2015-11-09 | 2022-04-29 | Scherer Technologies Llc R P | Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| CN109311976A (zh) * | 2016-06-20 | 2019-02-05 | 诺华股份有限公司 | 使用TNFα拮抗剂治疗干眼症的方法 |
| MX2019003727A (es) | 2016-09-29 | 2019-08-05 | Amgen Inc | Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas. |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| CN114401988A (zh) * | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
| CN112786101B (zh) * | 2019-11-07 | 2024-11-12 | 中国农业大学 | 热稳定性抗体的制备方法 |
| WO2021102131A1 (en) * | 2019-11-21 | 2021-05-27 | Brown University | Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US5644034A (en) | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
| US20030225254A1 (en) | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5213656A (en) | 1991-12-04 | 1993-05-25 | Gerber Scientific Products, Inc. | Method of using a web for etching of a surface |
| FI941169A7 (fi) * | 1992-07-13 | 1994-05-04 | Eukarion Inc | Lipidisoitujen proteiinien transvaskulaarinen ja intracellulaarinen an taminen |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| EP0614984B2 (en) | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| EP0938506B1 (en) * | 1996-07-16 | 2003-11-05 | Plückthun, Andreas, Prof. Dr. | Immunoglobulin superfamily domains and fragments with increased solubility |
| US6470213B1 (en) | 1999-03-30 | 2002-10-22 | Kenneth A. Alley | Implantable medical device |
| ATE273323T1 (de) | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| SG97908A1 (en) | 2000-08-03 | 2003-08-20 | Inst Data Storage | A method and apparatus for load/unload testing of disk drives |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| US6506412B2 (en) * | 2000-11-29 | 2003-01-14 | Sciencebased Health | Treatment of dry eye syndrome |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| PT2332989E (pt) | 2002-05-22 | 2015-08-05 | Esbatech Alcon Biomed Res Unit | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
| EP1539947A4 (en) | 2002-08-15 | 2006-09-06 | Epitomics Inc | HUMANIZED RABBIT ANTIBODIES |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US7060225B2 (en) | 2003-03-20 | 2006-06-13 | Northeastern Ohio Universities College Of Medicine | Self-contained assay device for rapid detection of biohazardous agents |
| DE10314412A1 (de) | 2003-03-28 | 2004-10-14 | Genovac Ag | Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern |
| US20050048578A1 (en) | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
| US20050033031A1 (en) | 2003-08-07 | 2005-02-10 | Couto Fernando Jose Rebelo Do | Methods for humanizing rabbit monoclonal antibodies |
| JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン，インコーポレーテッド | 抗体のヒト化 |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| DK2390267T3 (da) | 2005-06-07 | 2013-08-26 | Esbatech A Novartis Co Llc | Stabile og opløselige antistoffer, der hæmmer TNF(alfa) |
| BRPI0613382A8 (pt) | 2005-06-20 | 2018-01-02 | Genentech Inc | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| GB0520436D0 (en) | 2005-10-07 | 2005-11-16 | Photobiotics Ltd | Biological materials and uses thereof |
| CA2625222A1 (en) | 2005-10-11 | 2007-04-19 | Domantis Limited | Antibody polypeptide library screening and selected antibody polypeptides |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| EP2013236B1 (en) | 2006-04-28 | 2015-06-17 | Delenex Therapeutics AG | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
| EP1918302A3 (en) | 2006-05-18 | 2009-11-18 | AvantGen, Inc. | Methods for the identification and the isolation of epitope specific antibodies |
| WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| AU2007272224B2 (en) | 2006-07-10 | 2013-05-02 | Novartis Ag | scFv antibodies which pass epithelial and/or endothelial layers |
| NZ613356A (en) | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| WO2008063932A2 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| CN103275216B (zh) | 2007-03-12 | 2015-05-06 | 艾斯巴技术-诺华有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
| KR20100028571A (ko) | 2007-05-21 | 2010-03-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| KR101530723B1 (ko) | 2007-06-25 | 2015-06-22 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화 |
| DK2158315T3 (en) | 2007-06-25 | 2016-06-06 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies and modified antibodies with improved functional properties |
| US20090098136A1 (en) * | 2007-10-15 | 2009-04-16 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
| EP2799450A1 (en) * | 2007-12-31 | 2014-11-05 | Bayer Intellectual Property GmbH | Antibodies to TNFalpha |
| HUE038432T2 (hu) | 2008-06-25 | 2018-10-29 | Esbatech Alcon Biomed Res Unit | Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával |
| ES2687259T5 (es) * | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
| US9556265B2 (en) | 2008-06-25 | 2017-01-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| HRP20241467T1 (hr) | 2008-06-25 | 2025-01-03 | Novartis Ag | Stabilna i topljiva protutijela koja inhibiraju vegf |
| CA2729185A1 (en) | 2008-06-30 | 2010-01-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for modifying immunobinders |
| EP2303230A2 (en) | 2008-07-10 | 2011-04-06 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods and compositions for enhanced delivery of macromolecules |
| AU2010236256C1 (en) | 2009-04-16 | 2015-10-22 | Abbvie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
| WO2011075861A1 (en) | 2009-12-23 | 2011-06-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| EA030542B1 (ru) | 2010-07-15 | 2018-08-31 | Олег Ильич ЭПШТЕЙН | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии |
| UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| JP2014500712A (ja) | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| AR088512A1 (es) | 2011-10-24 | 2014-06-18 | Abbvie Inc | Anticuerpos dirigidos contra el tnf |
| BR112014009810A2 (pt) | 2011-10-24 | 2017-04-25 | Abbvie Inc | imunoligantes biespecíficos dirigidos contra tnf e il-17 |
-
2011
- 2011-10-20 UY UY0001033679A patent/UY33679A/es active IP Right Grant
- 2011-10-20 AR ARP110103885A patent/AR083495A1/es active IP Right Grant
- 2011-10-21 TW TW107135410A patent/TWI702230B/zh not_active IP Right Cessation
- 2011-10-21 US US13/278,500 patent/US8545849B2/en active Active
- 2011-10-21 TW TW104135587A patent/TWI652068B/zh not_active IP Right Cessation
- 2011-10-21 TW TW100138294A patent/TWI584816B/zh active
- 2011-10-24 KR KR1020197003613A patent/KR20190016137A/ko not_active Ceased
- 2011-10-24 PL PL11776322T patent/PL2630159T3/pl unknown
- 2011-10-24 UA UAA201304030A patent/UA111340C2/uk unknown
- 2011-10-24 AU AU2011318179A patent/AU2011318179B2/en active Active
- 2011-10-24 WO PCT/CH2011/000256 patent/WO2012051734A1/en not_active Ceased
- 2011-10-24 EP EP11776322.7A patent/EP2630159B1/en active Active
- 2011-10-24 KR KR1020137012905A patent/KR101635917B1/ko active Active
- 2011-10-24 MX MX2014008904A patent/MX351499B/es unknown
- 2011-10-24 BR BR112013010949-1A patent/BR112013010949B1/pt active IP Right Grant
- 2011-10-24 CN CN201180050388.0A patent/CN103154033B/zh active Active
- 2011-10-24 MX MX2013004295A patent/MX2013004295A/es active IP Right Grant
- 2011-10-24 KR KR1020177004318A patent/KR101947520B1/ko not_active Expired - Fee Related
- 2011-10-24 CN CN201810249347.8A patent/CN108359012B/zh active Active
- 2011-10-24 PH PH1/2013/500675A patent/PH12013500675B1/en unknown
- 2011-10-24 KR KR1020167017314A patent/KR20160083970A/ko not_active Ceased
- 2011-10-24 RU RU2013123266/10A patent/RU2558298C2/ru active
- 2011-10-24 RU RU2015119440/10A patent/RU2015119440A/ru not_active Application Discontinuation
- 2011-10-24 JP JP2013534142A patent/JP6245985B2/ja active Active
- 2011-10-24 CA CA2814766A patent/CA2814766C/en active Active
- 2011-10-24 EP EP17202052.1A patent/EP3336105B1/en active Active
-
2013
- 2013-04-09 ZA ZA2013/02537A patent/ZA201302537B/en unknown
- 2013-04-19 CL CL2013001089A patent/CL2013001089A1/es unknown
- 2013-04-22 CO CO13102367A patent/CO6741152A2/es unknown
- 2013-08-28 US US14/011,831 patent/US9598487B2/en active Active
-
2015
- 2015-07-31 JP JP2015151924A patent/JP2015193664A/ja not_active Withdrawn
- 2015-09-15 CL CL2015002735A patent/CL2015002735A1/es unknown
-
2016
- 2016-02-18 US US15/047,541 patent/US10570198B2/en active Active
-
2017
- 2017-07-24 JP JP2017142892A patent/JP7148228B2/ja active Active
-
2018
- 2018-02-22 CY CY20181100216T patent/CY1119941T1/el unknown
- 2018-12-05 JP JP2018227992A patent/JP2019054814A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013123266A (ru) | Стабильные и растворимые антитела | |
| JP2017530722A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2020527355A5 (enExample) | ||
| JP2021524268A5 (enExample) | ||
| JP2022101693A5 (enExample) | ||
| JP2022031784A5 (enExample) | ||
| JP2021525546A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| FI3618863T3 (fi) | Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi | |
| JP2020502271A5 (enExample) | ||
| JP2011501671A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2017500018A5 (enExample) | ||
| HRP20170615T1 (hr) | Stabilna i topiva protutijela koja inhibiraju vegf | |
| JP2011207882A5 (enExample) | ||
| JP2013537418A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2023071956A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| CN103890005A (zh) | 稳定的多抗原结合抗体 | |
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| JP2013519364A5 (enExample) |